3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
3
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
20
Carcinoma, Non-Small-Cell Lung
18
Neoplasms
10
Adenocarcinoma
8
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
6
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Breast Neoplasms
5
Colonic Neoplasms
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Melanoma
3
Liver Neoplasms
3
Biliary Tract Neoplasms
3
Ureteral Neoplasms
2
Solid Tumors
2
Sarcoma
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Non-small Cell Lung Cancer Metastatic
2
Malignant Solid Tumor
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Transitional Cell
2
Solid Tumor
1
Solid Cancer
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Interventions
Fluorouracil
12
pembrolizumab
9
Oxaliplatin
9
Nivolumab
9
Leucovorin
8
Capecitabine
7
Cisplatin
6
Trastuzumab
4
Paclitaxel
3
Drug Therapy
3
Docetaxel
3
zimberelimab
2
zanidatamab
2
tucatinib
2
spartalizumab
2
durvalumab
2
Radiotherapy
2
Levoleucovorin
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
zolbetuximab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
tezacitabine
1
ribociclib
1
quemliclustat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma Of Esophagus
×
Ramucirumab
×
Clear all
NCT04499924
2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3
Completed
17 enrolled
23 charts